AAN: Children With Generalized Seizures Improve With Zonegran (Zonisamide)
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AAN: Children With Generalized Seizures Improve With Zonegran (Zonisamide)

By Jill Stein
Special to DG News

PHILADLEPHIA, PA -- May 10, 2001 -- The antiepileptic drug, Zonegran (zonisamide), is safe and effective for the treatment of generalized seizures in children, according to data presented at the 53rd Annual Meeting of the American Academy of Neurology.

Dr. Angus A. Wilfong and associates conducted an open-label trial that included 45 patients actively followed through the epilepsy program at the Children’s Hospital of Wisconsin in Milwaukee.

All participants in the trial had diagnosed generalized seizures treated with various antiepileptic drugs (AEDs).

The mean age of the study population was 8.4 years. Most patients were diagnosed with symptomatic generalized epilepsy. Three patients with absence seizures had a diagnosis of idiopathic generalized epilepsy.

Investigators reviewed patients’ charts at enrollment to record age, current seizure frequency and AED therapy.

Patients were started on zonisamide at total daily doses ranging from 1 to 5 mg/kg per day with subsequent dosing titration to tolerability.

Zonisamide improved seizure frequency by more than 50 percent in 24 (60 percent) of 40 patients in whom data were available. Seventeen (42.5 percent) patients experienced a decrease in seizure frequency of greater than 75 percent or became seizure-free. In one patient, the number of seizures did not decrease but the seizures were less pronounced.

Results also showed that zonisamide provided improvement across several seizure types.

Lethargy and fatigue were the most common adverse events, occurring in eleven (27.5 percent) patients. Four (10 percent) patients experienced a decrease in appetite, three experienced cognitive slowing or confusion, and adverse behavioral effects were noted in two patients.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities